Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2026-08-19 16:10:06 ET · period of report 2026-08-17 · accession 0001221590-26-000025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-19 16:10 | 2026-08-17 | KROS | BIENAIME JEAN JACQUES | Dir | P - Purchase | $10.27 | +1,000 | 19.6K | +5% | +$10.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | P | A | 1,000 | $10.27 | 19,592 | D | — | — | (F1) Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |